Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.

Szczegóły
Abstrakt

Tytuł:: Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
Autorzy:: Kawada K; Department of Pharmacy, Kochi Medical Hospital School, 185-1 Kohasu, Oko town, Nankoku City, Kochi, Japan. jm-kei_.; Department of Biomedical Science, Kochi Medical Graduate School, 185-1 Kohasu, Oko town, Nankoku, Kochi, Japan. jm-kei_.
Ohta T; Department of Neurosurgery, Kochi Health Sciences Center, Ike 2125-1,, Kochi City, Kochi, Japan.
Fukuda H; Department of Neurosurgery, Kochi Medical Hospital School, 185-1 Kohasu, Oko town, Nankoku City, Kochi, Japan.
Hayashi T; Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, Japan.
Tanaka K; Pharmaceutical Department, Kochi Health Sciences Center, Ike 2125-1,, Kochi City, Kochi, Japan.
Imai T; Department of Hematology, Kochi Health Sciences Center, Ike 2125-1,, Kochi City, Kochi, Japan.
Morita Y; Department of Pharmacy, Kochi Medical Hospital School, 185-1 Kohasu, Oko town, Nankoku City, Kochi, Japan.
Miyamura M; Department of Pharmacy, Kochi Medical Hospital School, 185-1 Kohasu, Oko town, Nankoku City, Kochi, Japan.; Department of Biomedical Science, Kochi Medical Graduate School, 185-1 Kohasu, Oko town, Nankoku, Kochi, Japan.
Źródło:: Annals of hematology [Ann Hematol] 2020 Oct; Vol. 99 (10), pp. 2429-2436. Date of Electronic Publication: 2020 Aug 24.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York : Springer International, c1991-
MeSH Terms:: Antineoplastic Agents, Phytogenic/*adverse effects
Chloride Channel Agonists/*therapeutic use
Constipation/*drug therapy
Hematologic Neoplasms/*drug therapy
Lubiprostone/*therapeutic use
Lymphoma/*drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
Vinca Alkaloids/*adverse effects
Aged ; Aged, 80 and over ; Antineoplastic Agents, Phytogenic/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Constipation/chemically induced ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Drug Evaluation ; Drug Therapy, Combination ; Famotidine/therapeutic use ; Female ; Humans ; Laxatives/pharmacology ; Laxatives/therapeutic use ; Magnesium Oxide/therapeutic use ; Male ; Middle Aged ; Narcotics/adverse effects ; Prednisone/administration & dosage ; Propensity Score ; Proton Pump Inhibitors/therapeutic use ; Retrospective Studies ; Risk Factors ; Sennosides/therapeutic use ; Vinca Alkaloids/administration & dosage ; Vincristine/administration & dosage
References:: Kantarjian HM, Walters RS, Keating MJ, Smith TL, O'Brien S, Estey EH, Huh YO, Spinolo J, Dicke K, Barlogie B, McCredie KB, Freireich EJ (1990) Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 8:994–1004. https://doi.org/10.1200/JCO.1990.8.6.994. (PMID: 10.1200/JCO.1990.8.6.9942189958)
Geisler S, Doan RA, Strickland A, Huang X, Milbrandt J, DiAntonio A (2016) Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. Brain 139:3092–3108. https://doi.org/10.1093/brain/aww251. (PMID: 10.1093/brain/aww251277978105840884)
Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E (1994) Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 73:2515–2519. https://doi.org/10.1002/1097-0142(19940515)73:10<2515::aid-cncr2820731011>3.0.co;2-g. (PMID: 10.1002/1097-0142(19940515)73:10<2515::aid-cncr2820731011>3.0.co;2-g8174048)
Yamagishi A, Morita T, Miyashita M, Kimura F (2009) Symptom prevalence and longitudinal follow-up in cancer outpatients receiving chemotherapy. J Pain Symptom Manag 37:823–830. https://doi.org/10.1016/j.jpainsymman.2008.04.015. (PMID: 10.1016/j.jpainsymman.2008.04.015)
Toghill PJ, Burke JD (1970) Death from paralytic ileus following vincristine therapy. Postgrad Med J 46:330–331. https://doi.org/10.1136/pgmj.46.535.330. (PMID: 10.1136/pgmj.46.535.33052706802467012)
Anderson H, Scarffe JH, Lambert M, Smith DB, Chan CC, Chadwick G, McMahon A, Chang J, Crowther D, Swindell R (1987) VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies. Hematol Oncol 5:213–222. https://doi.org/10.1002/hon.2900050308. (PMID: 10.1002/hon.29000503083115884)
McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K (2016) Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol 7:414. https://doi.org/10.3389/fphar.2016.00414. (PMID: 10.3389/fphar.2016.00414278576915093116)
Yasu T, Ohno N, Kawamata T, Kurokawa Y (2016) Vincristine-induced paralytic ileus during induction therapy of treatment protocols for acute lymphoblastic leukemia in adult patients. Int J Clin Pharmacol Ther 54:471–473. https://doi.org/10.5414/CP202584. (PMID: 10.5414/CP20258427087157)
Hayashi H, Suzuki A, Ohata K, Ishihara M, Kubota Y, Kobayashi R, Shibata Y, Nakamura H, Nakamura N, Kitagawa J, Tsurumi H, Shimizu M, Itoh Y (2017) Control of constipation in patients receiving CHOP or CHOP-like chemotherapy regimens for non-Hodgkin’s lymphoma. Biol Pharm Bull 40:698–702. https://doi.org/10.1248/bpb.b16-01001. (PMID: 10.1248/bpb.b16-0100128458356)
Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R (2016) Bowel disorders. Gastroenterology 150:1393–1407. https://doi.org/10.1053/j.gastro.2016.02.031. (PMID: 10.1053/j.gastro.2016.02.031)
Legha SS (1986) Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1:421–427. https://doi.org/10.1007/bf03259853. (PMID: 10.1007/bf032598533540519)
Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol l7:903–909. https://doi.org/10.1016/S1470-2045(06)70910-X. (PMID: 10.1016/S1470-2045(06)70910-X)
Ikehara O (1992) Vincristine-induced paralytic ileus: role of fiberoptic colonoscopy and prostaglandin F2 alpha. Am J Gastroenterol 87:207–210. (PMID: 1734699)
Johanson JF, Ueno R (2007) Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 25:1351–1361. https://doi.org/10.1111/j.1365-2036.2007.03320.x. (PMID: 10.1111/j.1365-2036.2007.03320.x17509103)
Noergaard M, Traerup Andersen J, Jimenez-Solem E, Bring Christensen M (2019) Long term treatment with stimulant laxatives - clinical evidence for effectiveness and safety? Scand J Gastroenterol 54:27–34. https://doi.org/10.1080/00365521.2018.1563806. (PMID: 10.1080/00365521.2018.156380630700194)
Kurniawan I, Simadibrata M (2011) Management of chronic constipation in the elderly. Acta Med Indones 43:195–205. (PMID: 21979286)
Abernethy AP, Wheeler JL, Zafar SY (2009) Detailing of gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, new insights, and a proposed approach. Curr Opin Support Palliat Care 3:41–49. https://doi.org/10.1097/SPC.0b013e32832531ce. (PMID: 10.1097/SPC.0b013e32832531ce19365160)
Abramowitz L, Beziaud N, Labreze L, Giardina V, Caussé C, Chuberre B, Allaert FA, Perrot S (2013) Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ 16:1423–1433. https://doi.org/10.3111/13696998.2013.851082. (PMID: 10.3111/13696998.2013.85108224102123)
Johanson JF, Sonnenberg A, Koch TR (1989) Clinical epidemiology of chronic constipation. J Clin Gastroenterol 11:525–536. https://doi.org/10.1097/00004836-198910000-00008. (PMID: 10.1097/00004836-198910000-000082551954)
Şendir M, Büyükıylmaz F, Aştı T, Gürpınar Ş, Yazgan İ (2012) Postoperative constipation risk assessment in Turkish orthopedic patients. Gastroenterol Nurs 35:106–113. https://doi.org/10.1097/SGA.0b013e31824d2945. (PMID: 10.1097/SGA.0b013e31824d294522472670)
Dore MP, Pes GM, Bibbò S, Tedde P, Bassotti G (2018) Constipation in the elderly from northern Sardinia is positively associated with depression, malnutrition and female gender. Scand J Gastroenterol 53:797–802. https://doi.org/10.1080/00365521.2018.1473485. (PMID: 10.1080/00365521.2018.147348529779417)
Huang L, Jiang H, Zhu M, Wang B, Tong M, Li H, Lin MB, Li L (2017) Prevalence and risk factors of chronic constipation among women aged 50 years and older in Shanghai, China. Med Sci Monit 23:2660–2667. https://doi.org/10.12659/msm.904040. (PMID: 10.12659/msm.904040285625815462481)
Wald A (2016) Constipation: advances in diagnosis and treatment. JAMA 315:185–191. https://doi.org/10.1001/jama.2015.16994. (PMID: 10.1001/jama.2015.1699426757467)
Donald IP, Smith RG, Cruikshank JG, Elton RA, Stoddart ME (1985) A study of constipation in the elderly living at home. Gerontology 31:112–118. https://doi.org/10.1159/000212689. (PMID: 10.1159/0002126892987086)
Cardin F, Minicuci N, Droghi AT, Inelmen EM, Sergi G, Terranova O (2010) Constipation in the acutely hospitalized older patients. Arch Gerontol Geriatr 50:277–281. https://doi.org/10.1016/j.archger.2009.04.007. (PMID: 10.1016/j.archger.2009.04.00719481272)
Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, Oishi R, Sendo T, Araki H, Itoh Y, Japanese Study Group for the Relief of Opioid-induced Gastrointestinal Dysfunction (2012) A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain 28:373–381. https://doi.org/10.1097/AJP.0b013e318237d626. (PMID: 10.1097/AJP.0b013e318237d62622156893)
Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150–161. https://doi.org/10.1002/pst.433. (PMID: 10.1002/pst.43320925139)
Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083–3107. https://doi.org/10.1002/sim.3697. (PMID: 10.1002/sim.36971975744419757444)
Wickham RJ (2017) Managing constipation in adults with cancer. J Adv Pract Oncol 8:149–161. (PMID: 299000235995490)
Glia A, Lindberg G (1997) Quality of life in patients with different types of functional constipation. Scand J Gastroenterol 32:1083–1089. https://doi.org/10.3109/00365529709002985. (PMID: 10.3109/003655297090029859399387)
Koloski NA, Jones M, Wai R, Gill RS, Byles J, Talley NJ (2013) Impact of persistent constipation on health-related quality of life and mortality in older community-dwelling women. Am J Gastroenterol 108:1152–1158. https://doi.org/10.1038/ajg.2013.137. (PMID: 10.1038/ajg.2013.13723670115)
Sumida K, Molnar MZ, Potukuchi PK, Thomas F, Lu JL, Yamagata K, Kalantar-Zadeh K, Kovesdy CP (2018) Constipation and risk of death and cardiovascular events. Atherosclerosis 281:114–120. https://doi.org/10.1016/j.atherosclerosis.2018.12.021. (PMID: 10.1016/j.atherosclerosis.2018.12.021306581866399019)
Geisler S, Huang SX, Strickland A, Doan RA, Summers DW, Mao X, Park J, DiAntonio A, Milbrandt J (2019) Gene therapy targeting SARM1 blocks pathological axon degeneration in mice. J Exp Med 216:294–303. https://doi.org/10.1084/jem.20181040. (PMID: 10.1084/jem.20181040306429456363435)
Sharma RK (1988) Vincristine and gastrointestinal transit. Gastroenterology 95:1435–1436. (PMID: 10.1016/0016-5085(88)90404-0)
Esmadi M, Ahmad D, Hewlett A (2019) Efficacy of naldemedine for the treatment of opioid-induced constipation: a meta-analysis. J Gastrointest Liver Dis 28:41–46. https://doi.org/10.15403/jgld.2014.1121.281.any. (PMID: 10.15403/jgld.2014.1121.281.any)
Twycross R, Sykes N, Mihalyo M, Wilcock A (2012) Stimulant laxatives and opioid-induced constipation. J Pain Symptom Manag 43:306–313. https://doi.org/10.1016/j.jpainsymman.2011.12.002. (PMID: 10.1016/j.jpainsymman.2011.12.002)
Dosh SA (2002) Evaluation and treatment of constipation. J Fam Pract 51:555–559. (PMID: 12100780)
Contributed Indexing:: Keywords: Constipation; Hematological malignancy; Laxatives; Lubiprostone; Propensity score matching; Vinca alkaloids
Substance Nomenclature:: 0 (Antineoplastic Agents, Phytogenic)
0 (Chloride Channel Agonists)
0 (Laxatives)
0 (Narcotics)
0 (Proton Pump Inhibitors)
0 (Sennosides)
0 (Vinca Alkaloids)
3A3U0GI71G (Magnesium Oxide)
5J49Q6B70F (Vincristine)
5QZO15J2Z8 (Famotidine)
7662KG2R6K (Lubiprostone)
80168379AG (Doxorubicin)
8N3DW7272P (Cyclophosphamide)
VB0R961HZT (Prednisone)
SCR Protocol:: CHOP protocol
Entry Date(s):: Date Created: 20200826 Date Completed: 20200930 Latest Revision: 20210531
Update Code:: 20240105
DOI:: 10.1007/s00277-020-04222-z
PMID:: 32839869
: Czasopismo naukowe

Full Text Finder

Patients receiving vinca alkaloids for hematological malignancies frequently experience constipation that is unresponsive to laxatives. Research on treatment of vinca alkaloid-induced constipation is limited. This study aimed to determine whether the chloride channel activator lubiprostone ameliorates vinca alkaloid-induced constipation in patients with hematological malignancies. In this retrospective cohort study, vinca alkaloid-induced constipation (grade ≥ 3 using the Common Terminology Criteria for Adverse Events) was investigated in patients treated for hematological malignancies between July 2014 and June 2019 who had already been prescribed osmotic laxatives and additionally received either a stimulant laxative or lubiprostone. Univariate and multivariate analyses were performed to identify the risk factors for persistent constipation after introduction of the second laxative. A propensity score model was used to match 67 patients taking a stimulant laxative and 67 treated with lubiprostone, and the occurrence of intractable constipation was compared between groups. Overall, 203 patients were included, among whom 50 (25%) had constipation. On multivariate analysis, body mass index, opioid use, and addition of lubiprostone were independently associated with constipation. Patients treated with lubiprostone were significantly less likely to experience intractable constipation than did those treated with stimulant laxatives (10% vs. 34%, P = 0.002). Moreover, post-constipation diarrhea was significantly less frequent among patients treated with lubiprostone (42% vs. 63%, P = 0.024). Lubiprostone was more effective than stimulant laxatives at treating vinca alkaloid-induced intractable constipation in patients with hematological malignancies, and its use could enable safe vinca alkaloid chemotherapy.

Informacja